Ferrous sulfate: properties, uses, pros, cons, safety

Ferrous sulfate (generally iron(II) sulfate, FeSO₄) is an iron salt used in food mainly as a source of iron for fortification and, more often, as a raw material for dietary supplements (oral iron). The most common form is the heptahydrate (FeSO₄·7H₂O, blue-green crystals), while technical grades may also exist with different hydration states. In food applications, the key point is the bioavailability of iron (often good, but with potential sensory and gastrointestinal tolerability limits).

Definition

Ferrous sulfate is an inorganic compound made of the Fe²⁺ cation and the sulfate anion (SO₄²⁻). In water it releases ions that can be absorbed in the intestine; however, Fe²⁺ tends to oxidize to Fe³⁺ in the presence of oxygen and humidity, which can affect stability, color, and in some cases reactivity in food matrices.

Production process

Industrially, ferrous sulfate can arise as a by-product of metallurgical processes (e.g., pickling) or be produced in a controlled manner to achieve food grade or pharma grade quality. In practice it is obtained by reacting iron compounds/solutions with sulfuric acid, followed by purification, crystallization (often as heptahydrate), and possible drying to the desired hydration specification. For food use, critical controls include impurities (heavy metals), oxidation state, and moisture.

Key constituents

In a properly specified product, the “constituents” correspond to the salt itself: FeSO₄ (with different hydration states) and water of crystallization when present. The most relevant practical variables are not “components” but the oxidation state (maintenance of Fe²⁺) and trace impurities covered by specification.

Identification data and specifications

Physicochemical properties (indicative)

Functional role and mechanism of action

From a nutritional standpoint, ferrous sulfate is a carrier of bioavailable iron: in gastric and intestinal environments it releases Fe²⁺, which can enter non-heme iron absorption pathways. Real-world absorption depends on dietary factors: vitamin C generally supports non-heme iron availability, while phytates/polyphenols (in some cereals, legumes, tea) can reduce it.

From a technological standpoint, iron (as Fe²⁺/Fe³⁺) can catalyze oxidation reactions: in some formulations this requires attention because it may affect lipid stability (rancidity), color, and metallic notes.

Main uses

• Food fortification: used as an iron source where permitted in anemia and appropriate from a sensory and stability perspective (strongly matrix-dependent).

• Dietary supplements: one of the most widely used sources to provide iron; often paired with strategies to improve tolerability and adherence (dose, form, timing).

• Pharmaceutical context (use case): historically a reference for oral supplementation in iron deficiency; clinical use and therapeutic dosing are medical topics, but they explain its broad adoption as an efficacy benchmark.

Pros and cons

Pros

• Generally competitive cost and high availability.

• Bioavailability of non-heme iron is often considered good versus some other inorganic sources.

• “Simple” chemistry and strong standardization potential (helpful for quality control).

Cons

• Possible dose-dependent gastrointestinal effects: nausea, discomfort, constipation/diarrhea (high inter-individual variability).

• Potential sensory/technological impact in some matrices: metallic taste, interactions with pigments, and oxidation issues.

• Need for careful stability management (humidity/oxygen) to limit oxidation and color shifts.

Safety, regulatory, and practical labeling aspects

From a food safety perspective, the core issue is not allergenicity (it is not an allergen in a label-declarable sense) but excess iron in predisposed individuals and appropriate dose management.

Contexts requiring particular caution (general information, not a substitute for medical advice):

• conditions involving iron overload (e.g., hemochromatosis) or unexplained elevated ferritin;

• concomitant use with certain medicines (iron can reduce absorption of some drugs if taken together; dosing is often separated);

• children: extra care with formulations and prevention of accidental ingestion.

In the EU, iron can be added to foods and authorized sources include ferrous sulfate as a mineral substance for the addition of vitamins and minerals, within the applicable fortification framework.

Conclusion

Ferrous sulfate is a technically effective and widely used iron source, with a typical trade-off: strong nutritional usefulness and broad availability, balanced against the need to manage gastrointestinal tolerability, total dose, and potential effects on food stability/sensory profile. In food formulation, it should always be evaluated against the specific matrix (stability and taste) and the target population (needs and excess-risk considerations).

Mini-glossary

• Fe²⁺ (divalent iron): iron form more directly involved in non-heme iron absorption; can oxidize to Fe³⁺.

• Fe³⁺ (trivalent iron): oxidized form; can have different solubility/reactivity and influence color and stability.

• Fortification: intentional addition of micronutrients to a food to increase its nutritional content.

• Bioavailability: fraction of a nutrient that is effectively absorbed and utilized by the body.

References__________________________________________________________________________

Paesano R, Berlutti F, Pietropaoli M, Pantanella F, Pacifici E, Goolsbee W, Valenti P. Lactoferrin efficacy versus ferrous sulfate in curing iron deficiency and iron deficiency anemia in pregnant women. Biometals. 2010 Jun;23(3):411-7. doi: 10.1007/s10534-010-9335-z. 

Abstract. Iron deficiency (ID) and iron deficiency anemia (IDA) are the most common iron disorders throughout the world. ID and IDA, particularly caused by increased iron requirements during pregnancy, represent a high risk for preterm delivery, fetal growth retardation, low birth weight, and inferior neonatal health. Oral administration of ferrous sulfate to cure ID and IDA in pregnancy often fails to increase hematological parameters, causes adverse effects and increases inflammation. Recently, we have demonstrated safety and efficacy of oral administration of 30% iron saturated bovine lactoferrin (bLf) in pregnant women suffering from ID and IDA. Oral administration of bLf significantly increases the number of red blood cells, hemoglobin, total serum iron and serum ferritin already after 30 days of the treatment. The increasing of hematological values by bLf is related to the decrease of serum IL-6 and the increase of serum hepcidin, detected as prohepcidin, whereas ferrous sulfate increases IL-6 and fails to increase hematological parameters and prohepcidin. bLf is a more effective and safer alternative than ferrous sulfate for treating ID and IDA in pregnant women.

Cirillo L, Somma C, Allinovi M, Bagalà A, Ferro G, Di Marcantonio E, Bellelli S, Dallari LA, Ballo P, Dattolo PC. Ferric carboxymaltose vs. ferrous sulfate for the treatment of anemia in advanced chronic kidney disease: an observational retrospective study and cost analysis. Sci Rep. 2021 Apr 2;11(1):7463. doi: 10.1038/s41598-021-86769-z. 

Abstract. In non-dialysis-dependent chronic kidney disease (NDD-CKD), erythropoiesis-stimulating agents (ESAs) and iron supplementation are essential for anemia management. Ferric carboxymaltose (FCM) is a relatively novel intravenous iron formulation used in different clinical settings, although scarce data exist in NDD-CKD patients. Primary objective of this study was to retrospectively evaluate the efficacy of FCM compared with oral ferrous sulfate for the treatment of iron-deficiency anemia in a cohort of NDD-CKD patients, considering also the treatment costs. This was a monocentric, retrospective observational study reviewing 349 NDD-CKD patients attending an outpatient clinic between June 2013 and December 2016. Patients were treated by either FCM intravenous infusion or oral ferrous sulfate. We collected serum values of hemoglobin, ferritin and transferrin saturation (TSAT) and ESAs doses at 12 and 18 months. The costs related to both treatments were also analysed. 239 patients were treated with FCM intravenous infusion and 110 patients with oral ferrous sulfate. The two groups were not statistically different for age, BMI and eGFR values. At 18 months, hemoglobin, serum ferritin and TSAT values increased significantly from baseline in the FCM group, compared with the ferrous sulfate group. ESAs dose and rate of infusion decreased only in the FCM group. At 18 months, the treatment costs, analysed per week, was higher in the ferrous sulfate group, compared with the FCM group, and this was mostly due to a reduction in ESAs prescription in the FCM group. Routine intravenous FCM treatment in an outpatient clinic of NDD-CKD patients results in better correction of iron-deficiency anemia when compared to ferrous sulfate. In addition to this, treating NDD-CKD patients with FCM leads to a significant reduction of the treatment costs by reducing ESAs use.

Tolkien Z, Stecher L, Mander AP, Pereira DI, Powell JJ. Ferrous sulfate supplementation causes significant gastrointestinal side-effects in adults: a systematic review and meta-analysis. PLoS One. 2015 Feb 20;10(2):e0117383. doi: 10.1371/journal.pone.0117383.

Abstract. Background: The tolerability of oral iron supplementation for the treatment of iron deficiency anemia is disputed. Objective: Our aim was to quantify the odds of GI side-effects in adults related to current gold standard oral iron therapy, namely ferrous sulfate. Methods: Systematic review and meta-analysis of randomized controlled trials (RCTs) evaluating GI side-effects that included ferrous sulfate and a comparator that was either placebo or intravenous (i.v.) iron. Random effects meta-analysis modelling was undertaken and study heterogeneity was summarised using I2 statistics. Results: Forty three trials comprising 6831 adult participants were included. Twenty trials (n = 3168) had a placebo arm and twenty three trials (n = 3663) had an active comparator arm of i.v. iron. Ferrous sulfate supplementation significantly increased risk of GI side-effects versus placebo with an odds ratio (OR) of 2.32 [95% CI 1.74-3.08, p<0.0001, I2 = 53.6%] and versus i.v. iron with an OR of 3.05 [95% CI 2.07-4.48, p<0.0001, I2 = 41.6%]. Subgroup analysis in IBD patients showed a similar effect versus i.v. iron (OR = 3.14, 95% CI 1.34-7.36, p = 0.008, I2 = 0%). Likewise, subgroup analysis of pooled data from 7 RCTs in pregnant women (n = 1028) showed a statistically significant increased risk of GI side-effects for ferrous sulfate although there was marked heterogeneity in the data (OR = 3.33, 95% CI 1.19-9.28, p = 0.02, I2 = 66.1%). Meta-regression did not provide significant evidence of an association between the study OR and the iron dose. Conclusions: Our meta-analysis confirms that ferrous sulfate is associated with a significant increase in gastrointestinal-specific side-effects but does not find a relationship with dose.

Auerbach M, DeLoughery TG, Tirnauer JS. Iron Deficiency in Adults: A Review. JAMA. 2025 May 27;333(20):1813-1823. doi: 10.1001/jama.2025.0452.

Abstract. Importance: Absolute iron deficiency, defined as low iron stores with or without anemia, affects approximately 2 billion people worldwide and 14% of adults in the US. Iron-deficiency anemia, defined as low hemoglobin due to low iron stores, affects approximately 1.2 billion people worldwide, including 10 million in the US. Observations: Absolute iron deficiency progresses from low iron stores to iron-deficiency anemia. Individuals with nonanemic iron deficiency or iron-deficiency anemia may be asymptomatic or experience fatigue, irritability, depression, difficulty concentrating, restless legs syndrome (32%-40%), pica (40%-50%), dyspnea, lightheadedness, exercise intolerance, and worsening heart failure (HF). Symptom prevalences vary depending on age, comorbidities (eg, chronic kidney disease [CKD], HF), and severity and rate of development of iron deficiency. The most common causes of iron deficiency are bleeding (menstrual, gastrointestinal), impaired iron absorption (atrophic gastritis, celiac disease, bariatric surgical procedures), inadequate dietary iron intake, and pregnancy. In high-income countries, approximately 38% of nonpregnant, reproductive-age women have iron deficiency without anemia and about 13% have iron-deficiency anemia. During the third trimester of pregnancy, iron deficiency affects up to 84% of pregnant women, based on data from high-income countries. Additional risk factors include use of nonsteroidal anti-inflammatory drugs, inflammatory bowel disease (IBD [13%-90%]), and other chronic inflammatory conditions, such as CKD (24%-85%), HF (37%-61%), and cancer (18%-82%). Testing for iron deficiency is indicated for patients with anemia and/or symptoms of iron deficiency (fatigue, pica, or restless legs syndrome) and should be considered for those with risk factors such as heavy menstrual bleeding, pregnancy, or IBD. Iron deficiency is diagnosed by low serum ferritin (typically <30 ng/mL) in individuals without inflammatory conditions or by transferrin saturation (iron/total iron binding capacity × 100) less than 20%. Causes of iron deficiency should be identified and treated. Oral iron (ferrous sulfate 325 mg/d or on alternate days) is typically first-line therapy. Intravenous iron is indicated for patients with oral iron intolerance, poor absorption (celiac disease, post-bariatric surgical procedure), chronic inflammatory conditions (CKD, HF, IBD, cancer), ongoing blood loss, and during the second and third trimesters of pregnancy. Conclusions and relevance: Iron deficiency and iron-deficiency anemia are common conditions that may cause symptoms such as fatigue, exercise intolerance, and difficulty concentrating. Ferritin and/or transferrin saturation are required for diagnosis and screening. Oral iron is first-line therapy for most patients. Intravenous iron is used for individuals who do not tolerate or have impaired absorption of oral iron, those with ongoing blood loss, certain chronic inflammatory conditions (IBD, CKD, HF, cancer), and during the second and third trimesters of pregnancy.